Navigation Links
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Date:6/13/2008

NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS) had been presented at the 13th Congress of the European Hematology Association (EHA) at the Bella Center in Copenhagen, Denmark. At the Congress, data were presented in a subset of 26 patients with high-risk MDS by French-American-British (FAB) Group criteria.

The median age of the patients in the subset was 71 years (range of 59-82 years). Twelve patients were diagnosed with refractory anemia with excess blasts (RAEB) and 9 patients were diagnosed with RAEB-t. Five patients were diagnosed with either chronic myelomonocytic leukemias (CMML) (3) or as unknown (2). Fifteen patients had intermediate cytogenetics and 11 had unfavorable cytogenetics. Sixteen of the patients were classified as Intermediate-2 risk by the International Prognostic Scoring System (IPSS) system (1.5-2.0), and 10 were classified as high risk (greater than or equal to 2.5).

Eight of the 26 patients had received prior treatment for their disease. Prior agents used included arsenic trioxide, thalidomide, Ara-C, imatinib mesylate, interferon, amifostine, melphalan, hydroxyurea and 5-azacitiadine.

The overall complete response rate was 38% (7 CR and 3 CRp). Three of 10 responders received prior treatment; 8 of the 10 responders received consolidation. The median (range) of overall survival for the entire patient group was 3.4 months (0.6-28.6) and the median (range) of overall survival for responders was 3.9 months (2.5-28.6).


'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... the United States will increase ... Growth will be primarily driven by expansion in the ... direct energy devices will be increasingly adopted due to ... launched. Other key findings from Decision Resources ...
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014  Eli ... Adocia (Euronext Paris: FR0011184241 – ADOC) today announced a ... known as BioChaperone Lispro, for treatment in people with ... on Adocia,s proprietary BioChaperone® technology and is currently in ... develop BioChaperone Lispro with the goal of optimizing glucose ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... Medical, Inc. (Nasdaq: NXTM ), a ... efforts of its home hemodialysis patients together with the ... in advocating for improvements in the quality of care ...   (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO) NxStage home ...
... 3, 2011 As 73% of all registered hospitals ... or less, collectively these hospitals account for the largest ... to emergency and medical care, the role of community ... sustain community healthcare with quality physicians and equipment, community ...
Cached Medicine Technology:NxStage System One Patients Join Patient Advocacy Groups on Capitol Hill 2NxStage System One Patients Join Patient Advocacy Groups on Capitol Hill 3Craneware Supports Forward-Thinking Community Hospital Executives to Strengthen U.S. Community Healthcare's Business Performance 2Craneware Supports Forward-Thinking Community Hospital Executives to Strengthen U.S. Community Healthcare's Business Performance 3
(Date:12/20/2014)... San Francisco, CA (PRWEB) December 20, 2014 ... a Social Innovation company just launched first birthday focused ... the services, “MERRY BIRTHDAY MESSAGE” launched in both US ... , MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , ... launching for everyone’s birthday around the world. , Features, ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Developers of ... release of a new plugin for Final Cut Pro ... , “TranSlice Volume 5 allows users to create hand ... it.” Said Christina Austin, CEO of Pixel Film Studios. ... of professionalism while maintaining an easy to use interface.” ...
(Date:12/20/2014)... Parker & Sons, Inc. a focused and ... in contractor services announces reaching a milestone by providing ... of Arizona. Parker and Sons is comprised of a ... make customer service the number one priority. The company ... with one service vehicle and has since grown to ...
(Date:12/19/2014)... 20, 2014 It’s very easy to become ... that is put to the wayside until Christmas and the ... that travel “itch” and that burning desire to just escape ... on their journey to Telluride with a no-fuss, affordable package. ... and from the resort, and ensure that all accommodations are ...
(Date:12/19/2014)... FL (PRWEB) December 19, 2014 ... Revitalizing Bedsheets are now available. Celliant, the world’s ... both sheets and pillowcases. , There are a ... proven additional circulation, increased oxygenation and balanced body ... faster healing and pain relief; enhanced athletic performance; ...
Breaking Medicine News(10 mins):Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2
... Aero Financial, Inc, a strategic advisory and finance & ... been retained as a strategic consulting partner by Only ... information and nutrition products.Pursuant to the consulting agreement, Aero ... of the company,s growth plans, including:, ...
... Industry Professionals Available for Comment on Health Reform under Obama ... ... LLP today published a brief entitled 10 Minutes on Health ... alter the employer-based insurance system, the advantages of universal healthcare ...
... Why? , ... (PRWEB) January 22, 2009 -- Web 2.0, Health 2.0, ... are appearing more and more in the healthcare space and many hospital ... their marketing plans as another way to increase market share and build ...
... SEATTLE, Jan. 22 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... by,Esmaeli, et al. online on January 15, 2009 in ... agent Zevalin (ibritumomab,tiuxetan) in a front-line setting for patients ... involved the conjunctiva or orbit,produced a complete response rate ...
... HealthSystem,Consortium (UHC) today announced that after a competitive ... measurement services to Avatar,International and Press Ganey Associates, ... with options to extend. The agreements are effective ... Under the agreements, Avatar and Press Ganey ...
... Gen. Eric K. Shinseki took the oath of office ... assuming the leadership of the Department of Veterans Affairs ... am addressing from my first day in office is ... century organization focused on the Nation,s Veterans as its ...
Cached Medicine News:Health News:Aero Financial Retained as Strategic Consultant by Only Natures Finest(TM) 2Health News:Media Alert: PricewaterhouseCoopers Publishes Brief on the Impact of Government Health Reform on U.S. Employers 2Health News:Media Alert: PricewaterhouseCoopers Publishes Brief on the Impact of Government Health Reform on U.S. Employers 3Health News:Media Alert: PricewaterhouseCoopers Publishes Brief on the Impact of Government Health Reform on U.S. Employers 4Health News:Hope is Not a Strategy: Neither is Web 2.0 for a Hospital 2Health News:Hope is Not a Strategy: Neither is Web 2.0 for a Hospital 3Health News:Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma 2Health News:Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma 3Health News:Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma 4Health News:University HealthSystem Consortium Announces Dual Award for Patient Satisfaction Measurement Services 2Health News:Shinseki Sworn In, Vows 21st Century Service to Veterans 2
4 mm blade. Flat handle....
9 mm button end blade. 15 mm long backcutting blade. Angled at 45 degrees. Flat handle. Designated most popular model or size....
10 mm blade, angled left. Flat handle....
4 mm blade. Bayonet. Flat handle....
Medicine Products: